|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II, reactive oxygen species, and other factors in the setting of DKD stimulate drastic increases in calcium influx through the TRPC6 channel, causing podocyte hypertrophy and foot process effacement.
|
31115705 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy.
|
22113528 |
2012 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The intrarenal renin-angiotensin system, in particular augmentation of angiotensinogen (AGT) in proximal tubular cells (PTC), plays a crucial role in the development of diabetic nephropathy.
|
30466736 |
2019 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The two main treatment strategies for prevention of diabetic nephropathy are improved glycaemic control and blood pressure lowering, particularly using drugs such angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.
|
12682618 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further, we discovered that the genes encoding the angiotensin-converting enzyme, angiotensinogen, and angiotensin II type I receptor have a significant combinational effect on conferring susceptibility to diabetic nephropathy.
|
17653210 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an attempt to overcome this interaction, we evaluated the short-term renoprotective effect in diabetic nephropathy of the angiotensin II receptor antagonist losartan in patients homozygous for the insertion or the deletion allele.
|
12081578 |
2002 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensinogen was selected because of the putative link between it and mild to moderate essential hypertension and nephrosclerosis; angiotensin-converting enzyme because of its possible contribution to diabetic nephropathy; and renin, the angiotensin II receptor, and kallikrein because of their roles in hypertension and renal perfusion.
|
8989734 |
1996 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
It is noteworthy that the efferent glomerular arteriole is 10 - 100 times more sensitive to the vasoconstrictive properties of angiotensin II than the afferent one and this might account for the consequently higher intra-glomerular capillary pressure, which is believed to be the cornerstone of diabetic nephropathy.
|
28177279 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data suggest the importance of the activated oxidative stress/AGT/RAS axis in the pathogenesis of diabetic nephropathy.
|
24284398 |
2013 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The blockade of angiotensin II (Ang II) is a major therapeutic strategy for diabetic nephropathy.
|
25148511 |
2014 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Supporting our previous findings, the modulation and ANGII-mediated crosstalk between ACE2 and ACE in DN progression was more evident in males.
|
29884907 |
2018 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors.
|
30961500 |
2020 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study has demonstrated, for the first time, that high glucose augments AGT in human RPTCs through HNF-5, which provides a potential therapeutic target for diabetic nephropathy.
|
29053707 |
2017 |
|
Diabetic Nephropathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the relationship between the gene polymorphism of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), or angiotensin II receptor (AT1R) and the progression of diabetic nephropathy in a multicenter trial of ethnically homogeneous Japanese patients with non-insulin-dependent diabetes (NIDDM).
|
10364706 |
1999 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The impact of polymorphisms in the genes coding for angiotensinogen (M235T), ACE (ID), and angiotensin II type 1 receptor (A(1166)-->C) on decline in GFR and doubling of s-creatinine or development of ESRD in patients with type 1 diabetes and diabetic nephropathy (DN) was tested.
|
14569094 |
2003 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that neither the M235T nor the T174M polymorphism in the angiotensinogen gene contributes to genetic susceptibility to diabetic nephropathy in white IDDM patients, whereas the TT genotype of the M235T is associated with elevated blood pressure in patients with diabetic nephropathy.
|
8593944 |
1996 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Neither the AGT TT genotype nor the T allele were associated with the progression of DN in either sex after adjusting for confounding factors.
|
18849600 |
2009 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphism M235T in the angiotensinogen gene, which is associated with higher expression of this gene, contributes to the risk of diabetic nephropathy in NIDDM men but not in women.
|
9535411 |
1998 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A substitution (M235T) polymorphism in angiotensinogen (AGT) may interact with ACE I/D polymorphism for the risk of diabetic nephropathy, but their prognostic values have to be established by follow-up studies.
|
11181802 |
2001 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Allelic frequencies of the ACE-D and AGT-235T alleles were similar between patients with and without nephropathy in either type of diabetes, and accordingly, there was no significant association between diabetic nephropathy and the ACE or AGT genotype.
|
9049480 |
1997 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 102 individuals were screened for the presence of the ACE I/D and AGT M235T polymorphism: 46 individuals who had type 2 DM with diabetic nephropathy and, as controls, 56 individuals who had type 2 DM without diabetic nephropathy.
|
18413162 |
2008 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gene-gene interaction between acetyl-coenzymeA carboxylase beta (ACACβ) gene, which is involved in fatty acid metabolism and angiotensin II receptors (AGTR1) gene, which mediates RAS proteins actions on renal tissue, polymorphism with DN have not been studied earlier.
|
23081748 |
2013 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study has shown that AGT M235T TT genotype and APO E ε 2/3 genotype may be linked to a risk for DN among Turkish population.
|
21500980 |
2011 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the role of the renin-angiotensin system (RAS) in diabetic nephropathy, we examined the association between diabetic nephropathy in a large cohort of Japanese type 2 diabetic patients and polymorphisms within the genes that encode angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II receptor type 1 (AGTR1).
|
17143591 |
2007 |
|
Diabetic Nephropathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggested that ACE I/D polymorphism, but not AGN M235T polymorphism, is a possible genetic risk factor for diabetic nephropathy in Japanese NIDDM patients.
|
8596493 |
1996 |